BioMarin Pharmaceuticals
BMRN
473 hedge funds and large institutions have $15.3B invested in BioMarin Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 149 increasing their positions, 187 reducing their positions, and 51 closing their positions.
29% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 51
16% more call options, than puts
Call options by funds: $138M | Put options by funds: $119M
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
3% more funds holding
Funds holding: 460 → 473 (+13)
1.23% less ownership
Funds ownership: 102% → 100.77% (-1.2%)
13% less capital invested
Capital invested by funds: $17.6B → $15.3B (-$2.29B)
20% less repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 187
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$124M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$91.6M |
| 3 |
Jennison Associates
New York
|
+$71.9M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$60.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$118M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$118M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$105M |
| 4 |
BlackRock
New York
|
-$51.8M |
| 5 |
MNG
Manning & Napier Group
Fairport,
New York
|
-$38.5M |
BMRN Hedge Fund Activity: Q4 2018 in Review
473 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2018, worth a combined $15.3B — down 13% from $17.6B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new BMRN positions and 51 closed out — a net gain of 15 holders — while 149 added to existing stakes and 187 trimmed.
The largest buyer was Capital International Investors, adding an estimated $124M. The largest seller was Capital Research Global Investors, cutting an estimated $118M.
- 473 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2018, up from 460 in Q3 2018.
- Funds reported $15.3B of BioMarin Pharmaceuticals stock for Q4 2018, down 13% quarter-over-quarter.
- 66 funds opened new BioMarin Pharmaceuticals positions in Q4 2018 and 51 closed out, a net change of +15 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2018 was Capital International Investors, an estimated $124M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2018 was Capital Research Global Investors, an estimated $118M sold.
Based on aggregated 13F filings for Q4 2018.